Navigation Links
EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 13, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that data from its Phase 3 trial of PRX-00023, a novel long-acting 5-HT1A agonist, was featured in a poster presentation at the 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Boca Raton, Florida. The meeting is sponsored by the National Institutes of Health and the American Society of Clinical Psychopharmacology.

The presentation highlighted data from a randomized, double-blind, placebo-controlled Phase 3 study of PRX-00023 in 311 patients with generalized anxiety disorder (GAD). Top-line results from the trial were announced in September 2006. The primary endpoint of the trial was change from baseline in the Hamilton Rating Scale for Anxiety (HAM-A). PRX-00023 showed a trend (p=0.116) to reduce the level of anxiety versus placebo based on the HAM-A; data from the trial also indicated a statistically significant change in the Montgomery Asberg Depression Rating Scale (MADRS), with p=0.0094. The MADRS measures symptoms of depression and was a pre-specified secondary endpoint in this trial. Results also indicated that PRX-00023 was well-tolerated, there was a low rate of discontinuation due to adverse events and side effects seen were similar to placebo, including impact on sexual function and sleep.

"Although PRX-00023 did not meet the primary endpoint in this Phase 3 trial, we were pleased by our secondary endpoint results - statistically significant MADRS data," said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. "The MADRS results encouraged us to accelerate our clinical plans for PRX-00023 in major depression. We look forward to the results of our ongoing depression trial in the first half of next year."

In March 2007, EPIX announced the initiation of a randomized, double-blind, placebo-controlled Phase 2b trial in 330 patients with major depressive d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Fortune Oil ... officially changed its name to Manzo Pharmaceuticals, Inc. with ... to take effect today, September 17, 2014. Also taking ... The approval is a pivotal event in ... . Mr. Manzo explained, "We could not proceed with ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... 2014 Mindray (NYSE: MR)announced its new generation ... system has been showcased for the first time at ... September, and is scheduled for availability in the U.S. ... the most efficient workhorse in the mid-range segment, the ... perfectly optimized user experience including a gesture-sensitive touch screen, ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
(Date:9/17/2014)... Oxford, UK, September 17, 2014 The International Journal ... has opened up its archive of previously published content: after ... read. A key aim of the IJS is ... hoped that by making these articles available to all will ... Editor-in-Chief of IJS said, "The journal has always ...
(Date:9/17/2014)... WA (PRWEB) September 17, 2014 A ... in fiscal year 2010 revealed 3.2% of these patients developed ... and 2.4% labeled as superficial SSIs. The average difference for ... 876, after adjustments. , The study, conducted by Marin Schweizer, ... the University of Iowa, found the treatment costs for the ...
(Date:9/17/2014)... September 17, 2014 The probability of ... with regular screening and examination, a healthy diet could ... of Epicure with the Chef MDs, renowned ... Paul Rusilko to prepare a delicious Fish Moilee. , ... diets that influence risk of prostate cancer, uncommonly found ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... September 17, 2014 Kamut International is ... a key ingredient in Michael Angelo’s new “Made With ... new fully organic lasagna ready made, frozen meal. Michael ... pastas and these new products align well with Kamut ... all KAMUT® Brand wheat must be grown certified organic. ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2
... A large-scale data review by researchers in China of ... the endoscopic procedure to be safe and effective for ... a pooled detection rate of 68.1 percent for all ... be the most common indication, with a relatively high ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 2011) Researchers in Japan have completed a study showing ... pulp can be grafted and produce bone regeneration between parents ... of Cell Transplantation (20:7), now freely ... a number of reasons, and autogenous bone grafting - using ...
... , MONDAY, Sept. 26 (HealthDay News) -- ... inhibitor (SSRI) antidepressants and antiplatelet drugs such as aspirin ... those who take anti-clotting drugs only, a new study ... and Lexapro. Antiplatelet drugs prevent blood cells from ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
... Eating fruits and vegetables may reduce the risk of some ... examined the diets of 918 colorectal cancer patients and 1,021 ... consumption of certain vegetables and fruits were associated with a ... -- that is, the upper and lower portions of the ...
Cached Medicine News:Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...
Medicine Products: